Abstracts tagged "SLE"

Abstract Number: 64 • 2019 ACR/ARP Annual Meeting
Rab4A Controls mTOR Pathway Activation, Pro-inflammatory Lineage Development, and Disease Pathogenesis in Lupus-prone Mice
Nick Huang¹, Zhiwei Lai ², Brandon Wyman ², Thomas Winans ², Manuel Duarte ², Joshua Lewis ², Mark Haas ³, Laurence Morel ⁴ and Andras Perl ⁵, ¹Upstate Medical University, Syracuse, NY, ²Upstate Medical University, Syracuse, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴University of Florida, Gainesville, FL, ⁵SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: Mouse models of SLE have been indispensable tools for studying disease pathogenesis; however, each model only recapitulates limited aspects of lupus. SLE1.2.3. (TC) mice…
Abstract Number: 673 • 2019 ACR/ARP Annual Meeting
Clinical Characteristics of Lymphadenopathy in Systemic Lupus Erythematous: A Case Control Study from a Tertiary Care Center
Elizabeth Graef¹, Daniel Magliulo ¹, Norris Hollie ¹, Chelsea Marcus ² and Vasileios Kyttaris ³, ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Beth Israel Deaconess Medical Center, Boston, ³Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: While lymphadenopathy and/or lymphadenitis (LAD) is considered a relatively common clinical finding in SLE patients, its clinical significance is poorly understood. Previous studies described…
Abstract Number: 1025 • 2019 ACR/ARP Annual Meeting
Dynamic Changes During SLE Flare Implicate Age-Associated B Cells and Altered T Follicular and Peripheral Helper Cell Responses in Disease Activity
Kieran Manion¹, Zahi Touma ², Dennisse Bonilla ², Dafna Gladman ³, Murray Urowitz ² and Joan Wither ⁴, ¹Krembil Research Institute, Toronto, ON, Canada, ²University Health Network, University of Toronto, Toronto, ON, Canada, ³Krembil Research Institute, U of Toronto, Toronto, ON, Canada, ⁴University Health Network, Krembil Research Institute, Toronto, ON, Canada
Background/Purpose: SLE is a chronic autoimmune disorder in which periods of relative disease inactivity are punctuated by flares that present with increased inflammation and tissue…
Abstract Number: 1586 • 2019 ACR/ARP Annual Meeting
All-cause Hospitalizations and Mortality in Systemic Lupus Erythematosus in the US- results from a National Inpatient Database
Rashmi Dhital¹, Dilli Ram Poudel ², Ramesh Kumar Pandey ³ and Paras Karmacharya ⁴, ¹Reading Hospital ,PA, Shillington, PA, ²University of Pennsylvania, Philadelphia, ³Fox Chase Hospital, Philadelphia, ⁴Reading Hospital, Mayo Clinic, Rochester
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic multisystem autoimmune disorder with variable presentation. While several studies have outlined the risk factors for hospitalization and…
Abstract Number: 2036 • 2019 ACR/ARP Annual Meeting
Mitochondrial DNA: A Potential Trigger of Cyclic GMP-AMP Synthase Activation in Systemic Lupus Erythematosus
Jie An¹, Bhargavi Duvvuri ¹, Xizhang Sun ¹, Lena Tanaka ¹, Christian Lood ¹ and Keith Elkon ¹, ¹University of Washington, Seattle
Background/Purpose: Approximately 70% of patients with Systemic Lupus Erythematosus (SLE) show a striking Type I Interferon (IFN-I) signature in peripheral blood. Although we have some…
Abstract Number: 65 • 2019 ACR/ARP Annual Meeting
CD6 Modulation Ameliorates Skin and Kidney Disease in a Spontaneous Murine Model of SLE
Samantha Chalmers¹, Sayra Garcia ¹, Rajalakshmy Ayilam Ramachandran ², Chandra Mohan ², Jeanette Ampudia ³, Cherie Ng ³, Stephen Connelly ³ and Chaim Putterman ⁴, ¹Albert Einstein College of Medicine, Bronx, NY, ²University of Houston, Houston, ³Equillium, Inc, San Diego, CA, ⁴Albert Einstein College of Medicine, New York, NY
Background/Purpose: T cells are an important contributor the pathogenesis of SLE and its various end organ manifestations. Thus, they present themselves as potential therapeutic targets;…
Abstract Number: 678 • 2019 ACR/ARP Annual Meeting
Performance of the EULAR/ACR 2019 Classification Criteria for Systemic Lupus Erythematosus in Men, Diverse Ethnicities, and Early Disease
Martin Aringer¹, Ralph Brinks ², Karen Costenbader ³, David Daikh ⁴, Dimitrios Boumpas ⁵, David Jayne ⁶, Diane Kamen ⁷, Marta Mosca ⁸, Rosalind Ramsey-Goldman ⁹, Josef Smolen ¹⁰, David Wofsy ¹¹, Betty Diamond ¹², Søren Jacobsen ¹³, W Joseph McCune ¹⁴, Guillermo Ruiz-Irastorza ¹⁵, Matthias Schneider ¹⁶, Murray Urowitz ¹⁷, George Bertsias ¹⁸, Bimba Hoyer ¹⁹, Nicolai Leuchten ²⁰, Chiara Tani ²¹, Sara K. Tedeschi ²², Zahi Touma ¹⁷, Branimir Anic ²³, Florence Assan ²⁴, Daniel TM Chan ²⁵, Ann E Clarke ²⁶, Mary Crow ²⁷, László Czirják ²⁸, Andrea Doria ²⁹, Winfried Graninger ³⁰, Bernadette Halda-Kiss ³¹, Sarfaraz Hasni ³², Peter Izmirly ³³, Michelle Jung ²⁶, Gabor Kumanovics ³¹, Xavier Mariette ³⁴, Ivan Padjen ²³, Jose Maria Pego-Reigosa ³⁵, Juanita Romero-Diaz ³⁶, Iñigo Rua Figueroa ³⁷, Raphaèle Seror ²⁴, Georg Stummvoll ¹⁰, Yoshiya Tanaka ³⁸, Maria Tektonidou ³⁹, Carlos Vasconcelos ⁴⁰, Edward Vital ⁴¹, Daniel Wallace ⁴², Sule Yavuz ⁴³ Raymond Naden ⁴⁴, Thomas Dörner ⁴⁵ and Sindhu R. Johnson ⁴⁶, ¹Division of Rheumatology, Department of Medicine III, University Medical Center & Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany, ²Department of Rheumatology and Hiller Research Unit of Rheumatology, UKD, Heinrich-Heine University, Düsseldorf, Germany, ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴University of California at San Francisco and VA Medical Center, San Francisco, CA, ⁵University of Athens, Athens, Greece, ⁶Vasculitis and Lupus Clinic, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom, ⁷Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, ⁸Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, Pisa, Italy, ⁹Northwestern University, Chicago, IL, ¹⁰Medical University of Vienna, Vienna, Austria, ¹¹UCSF, San Francisco, ¹²Feinstein Institutes for Medical Research, Manhasset, ¹³Copenhagen Lupus and Vasculitis Clinic, Copenhagen, Denmark, ¹⁴University of Michigan, Ann Arbor, MI, ¹⁵Autoimmune Diseases Unit, Hospital Universitario Cruces, Barakaldo, Spain, ¹⁶Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany, ¹⁷University Health Network, University of Toronto, Toronto, ON, Canada, ¹⁸University of Crete, Rheumatology, Clinical Immunology and Allergy Unit, Heraklion, Greece, ¹⁹University of Schleswig-Holstein at Kiel, and Charité – Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Kiel, Germany, ²⁰University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, ²¹Azienda Ospedaliero Universitaria Pisana, University of Pisa, Pisa, Italy, ²²Brigham and Women's Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, ²³UHC Zagreb and University of Zagreb School of Medicine, Zagreb, Croatia, ²⁴Université Paris Sud, Hôpitaux Universitaires Paris-Sud, AP-HP, INSERM UMR 1184, Le Kremlin-Bicêtre, France, ²⁵University of Hong Kong, Hong Kong, Hong Kong, ²⁶University of Calgary, Calgary, AB, Canada, ²⁷Hospital for Special Surgery, New York, NY, ²⁸Dept. of Rheumatology and Immunology, University of Pécs, Pécs, Hungary, ²⁹University and Azienda Ospedaliera of Padova, Padova, Italy, ³⁰Medical University of Graz, Graz, Austria, ³¹University of Pécs, Pécs, Hungary, ³²NIAMS, National Institutes of Health, Bethesda, MD, ³³NYU School of Medicine, New York, ³⁴Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, ³⁵Complexo Hospitalario Universitario, Vigo, Spain, ³⁶Instituto Nacional de Ciencias Medicas y Nutricion Salvador, Zubiran Vasco de Quiroga, Mexico City, Mexico, ³⁷Hospital Doctor Negrin, Las Palmas, ³⁸University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³⁹First Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, ⁴⁰University of Porto, UMIB Abel Salazar Biomedical Sciences Institute, Porto, Portugal, ⁴¹University of Leeds, Leeds, United Kingdom, ⁴²Cedars-Sinai Medical Center/University California at Los Angeles, Los Angeles, CA, ⁴³Uppsala University, Istanbul, Turkey, ⁴⁴McMaster University, Hamilton, ON, Canada, ⁴⁵Charite Universitätsmedizin Berlin and DRFZ, Berlin, Germany, ⁴⁶Toronto Scleroderma Program, Department of Medicine, Toronto Western and Mount Sinai Hospitals, University of Toronto, Toronto, Canada
Background/Purpose: The EULAR/ACR 2019 Classification Criteria for SLE have been validated in an international cohort of 696 SLE patients and 574 non-SLE patients with a…
Abstract Number: 1033 • 2019 ACR/ARP Annual Meeting
Mass Cytometric Immunophenotyping Highlights a Dysregulated T cell-B Cell Axis in Patients with New-onset Lupus
Ye Cao¹, Stephen Alves ², Corine Sinnette ³, Cameron Speyer ³, Gregory Keras ¹, Yujie Qu ², Joshua Keegan ⁴, James Lederer ⁴, Deepak Rao ³ and Karen Costenbader ³, ¹Brigham and Women's Hospital, Boston, ²Merck, boston, ³Brigham and Women's Hospital, Boston, MA, ⁴BWH, Boston
Background/Purpose: The immune cell subsets most altered early in SLE disease course remain unclear. Defining abnormalities in lymphocyte populations in patients with new-onset SLE may…
Abstract Number: 1591 • 2019 ACR/ARP Annual Meeting
Anti-ovarian Antibodies Are Not Associated with Premature Menopause in SLE Treated with Cyclophophosphamide
Martha Tsaliki ¹, Kristi Koelsch ¹, Ambre Chambers ¹, Mitali Talsania ², Eliza Chakravarty ³ and Robert Scofield³, ¹University of Oklahoma health Sciences Center, Oklahoma City, OK, ²University of Oklahoma Health Sciences Center, Oklahoam City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Treatment of systemic lupus erythematosus (SLE) with cyclophosphamide is associated with premature menopause, especially those at an older age of treatment and those receiving…
Abstract Number: 2041 • 2019 ACR/ARP Annual Meeting
Epigenome-wide Association Study Reveals Differential DNA Methylation in Systemic Lupus Erythematosus Patients with a History of Ischemic Heart Disease
Juliana Imgenberg-Kreuz¹, Christopher Sjöwall ², Martina Frodlund ², Iva Gunnarsson ³, Elisabet Svenungsson ⁴ and Dag Leonard ¹, ¹Department of Medical Sciences, Section of Rheumatology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden, ²Department of Clinical and Experimental Medicine, Rheumatology/Division of Neuro and Inflammation Sciences, Linköping University, Linköping, Sweden, ³Department of Medicine Solna, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁴Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have an increased risk of ischemic heart disease (IHD). Altered methylation patterns have been reported both in SLE,…
Abstract Number: 66 • 2019 ACR/ARP Annual Meeting
Amelioration of Immune Complex-Mediated Glomerulonephritis by CD6 Modulation
Samantha Chalmers¹, Sayra Garcia ¹, Jeanette Ampudia ², Cherie Ng ², Stephen Connelly ² and Chaim Putterman ³, ¹Albert Einstein College of Medicine, Bronx, NY, ²Equillium, Inc, San Diego, CA, ³Albert Einstein College of Medicine, New York, NY
Background/Purpose: CD6 is a co-stimulatory receptor on T cells, that binds to activated leukocyte cell adhesion molecule (ALCAM), a ligand expressed on antigen presentation cells…
Abstract Number: 687 • 2019 ACR/ARP Annual Meeting
CCP Autoantibody Positive SLE Patients Show Unique Enrichments in SLE Criteria and Autoantibody Biomarkers That Vary by Race
John Goetzinger¹, Carla J. Guthridge ², Wade DeJager ², Eliza F. Chakravarty ³, Cristina Arriens ³, Teresa Aberle ², Aikaterini Thanou ², Joan T. Merrill ⁴ and Judith James ³, ¹University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Okalahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Anti-cyclic citrullinated peptide (anti-CCP) antibodies are a hallmark of RA but are widely distributed in other autoimmune diseases. Although SLE is well characterized as…
Abstract Number: 1039 • 2019 ACR/ARP Annual Meeting
Molecular Profiling Identifies Immunologic Subgroups and Informs Mechanism of Action of Baricitinib in SLE
Thomas Dörner¹, Yoshiya Tanaka ², Michelle Petri ³, Josef Smolen ⁴, Daniel Wallace ⁵, Ernst Dow ⁶, Damiano Fantini ⁶, Richard Higgs ⁶, Guilherme Rocha ⁶, Brenda Crowe ⁶, Robert Benschop ⁶, Adam Abel ⁶, Nicole Byers ⁶, Maria Silk ⁶, Stephanie de Bono ⁶ and Robert Hoffman ⁶, ¹Charite Universitätsmedizin Berlin and DRFZ, Berlin, Germany, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Medical University of Vienna, Vienna, Austria, ⁵Cedars-Sinai Medical Center/University California at Los Angeles, Los Angeles, CA, ⁶Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib is an oral selective Janus kinase (JAK) 1 and JAK2 inhibitor. In the Phase II, 24-week, randomized, placebo-controlled, double-blind study JAHH (NCT02708095), once-daily…
Abstract Number: 1593 • 2019 ACR/ARP Annual Meeting
Heart Rate Visit-to-Visit Variability in Patients with Systemic Lupus Erythematosus Is Associated with Increased Mortality
Tyler Reese¹, Alyson Dickson ¹, Jocelyn Gandelman ¹, Sarah Bayefsky ¹, April Barnado ¹, Katherine Barker ¹, C. Michael Stein ¹, Vivian Kawai ¹ and Cecilia Chung ¹, ¹Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have increased mortality compared to the general population. Heart rate visit-to-visit variability (HRVVV) has emerged as an adverse…
Abstract Number: 2042 • 2019 ACR/ARP Annual Meeting
Intestinal Microbiota Alters Th1/Th17 Balance but Is Dispensable for the Development of Systemic Autoimmune Disease in BXD2 Mice
Huixian Hong¹, Qi Wu ¹, PingAr Yang ¹, Bao Luo ², Alex Essman ², Oluwagbemiga Ojo ², Michael R. Crowley ³, David K. Crossman ³, Casey D. Morrow ⁴, Jeremy B. Foote ⁵, Trenton R. Schoeb ⁶, Charles O. Elson ⁷, Hui-Chen Hsu ⁸ and John D. Mountz ⁹, ¹Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, ³Department of Genetics, University of Alabama at Birmingham, Birmingham, ⁴Department of Cell, Developmental, and Integrative Biology, University of Alabama at Birmingham, Birmingham, ⁵Department of Microbiology, University of Alabama at Birmingham, Birmingham, ⁶Department of Genetics, Animal Resources Program, University of Alabama at Birmingham, Birmingham, ⁷Department of Medicine, University of Alabama at Birmingham, Birmingham, ⁸1Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, ⁹Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham & University of Alabama at Birmingham and Birmingham VA Medical center, Birmingham
Background/Purpose: Intestinal microbiota dysbiosis has been implicated in the pathogenesis of autoimmune disease. How the microbiota affects the peripheral immune system leading to the development…

1
2
3
…
38
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].